A unifying vision of cancer therapy for the 21st century

Journal of Clinical Oncology

Volumn 17, Issue 11 SUPPL., 1999, Pages 13-21

  Alberts, David S ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; ASCORBIC ACID; BETA CAROTENE; CALCIUM CARBONATE; CELECOXIB; CISPLATIN; DOXORUBICIN; FOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; SELENIUM; SULINDAC;

CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; COLON CANCER; CONFERENCE PAPER; DIET; HEALTH PROMOTION; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIFESTYLE; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; OVARIAN NEOPLASMS; RESEARCH;

EID: 0032728885     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (49)

1. Landis SH, Murray T, Bolden S, et al: Cancer statistics, 1999. CA Cancer J Clin 49:8-31, 1999
2. List AF, Kopecky KJ, Willman CL, et al: Benefit of cyclosporin (CsA) modulation of anthracycline resistance in high-risk AML: A Southwest Oncology Group (SWOG) Study. Presented at the 40th Annual Meeting of the American Society of Hematology, Miami Beach, FL, December 3-8, 1998
3. Alberts DS, Chang SY, Chen HS, et al: Oral melphalan kinetics. Clin Pharmacol Ther 26:737-745, 1979
4. Alberts DS, Mason-Liddil N, O'Toole RV, et al: Randomized phase III trial of chemoimmunotherapy in patients with previously untreated stages III and IV suboptimal disease ovarian cancer: A Southwest Oncology Group study. Gynecol Oncol 32:8-15, 1989
5. Alberts D, Mason N, Surwit E, et al: Phase I trial of carboplatin-cyclophosphamide and iproplatin- cyclophosphamide in advanced ovarian cancer: A Southwest Oncology Group study. Cancer Treat Rev 12:83-92, 1985 (suppl A)
6. Alberts DS, Green S, Hannigan EV, et al: Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10:706-717, 1992 (published erratum appears in J Clin Oncol 10:1505, 1992)
7. Alberts D, Hannigan E, Canetta R, et al: Cisplatin versus carboplatin in advanced ovarian cancer: An economic analysis. Pharm Ther 19:692-706, 1994
8. Howell SB, Pfeifle CL, Wung WE, et al: Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97:845-851, 1982
9. Alberts DS, Liu PY, Hannigan EV, et al: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950-1955, 1996
10. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
11. Markman M, Bundy B, Benda J, et al: Randomized phase 3 study of intravenous (IV) cisplatin (CIS)/paclitaxel (PAC) versus moderately high dose IV carboplatin (CARB) followed by IV PAC and intrapentoneal (IP) CIS in optimal residual ovarian cancer (OC): An intergroup trial (GOG, SWOG, ECOG). Proc Am Soc Clin Oncol 17:361a, 1998 (abstr 1392)
12. Korst AE, Eeltink CM, Vermorken JB, et al: Pharmacokinetics of amifostine and its metabolites in patients. Eur J Cancer 33:1425-1429, 1997
13. List AF, Heaton R, Glinsmann-Gibson B, et al: Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors. Leukemia 12:1596-1602, 1998
14. DiPaola RS, Schuchter L: Neurologic protection by amifostine. Semin Oncol 26:82-88, 1999
15. Giovannucci E, Rimm EB, Stampfer MJ, et al: Intake of fat, meat, and fiber in relation to risk of colon cancer in men. Cancer Res 54:2390-2397, 1994
16. Howe GR, Benito E, Castelleto R, et al: Dietary intake of fiber and decreased risk of cancers of the colon and rectum: Evidence from the combined analysis of 13 case-control studies. J Natl Cancer Inst 84:1887-1896, 1992
17. Sorenson AW, Slattery ML, Ford MH: Calcium and colon cancer: A review. Nutr Cancer 11:135-145, 1988
18. Arminski TC, McLean DW: Incidence and distribution of adenomatous polyps of the colon and rectum based on 1,000 autopsy examinations. Dis Colon Rectum 7:249-261, 1964
19. Holtzman R, Poulard JB, Bank S, et al: Repeat colonoscopy after endoscopic polypectomy. Dis Colon Rectum 30:185-188, 1987
20. Nava H, Carlsson G, Petrelli NJ, et al: Follow-up colonoscopy in patients with colorectal adenomatous polyps. Dis Colon Rectum 30:465-468, 1987
21. Byers T, Levin B, Rothenberger D, et al: American Cancer Society guidelines for screening and surveillance for early detection of colorectal polyps and cancer: Update 1997 - American Cancer Society Detection and Treatment Advisory Group on Colorectal Cancer. CA Cancer J Clin 47:154-160, 1997
22. Winawer SJ, Zauber AG, Ho MN, et al: Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med 329:1977-1981, 1993
23. Stryker SJ, Wolff BG, Gulp CE, et al: Natural history of untreated colonic polyps. Gastroenterology 93:1009-1013, 1987
24. Atkin WS, Morson BC, Cuzick J: Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 326:658-662, 1992
25. Gloeckler-Ries LA, Hankey BF, Edwards BK: Cancer Statistics Review, 1973-1987 (DHHS publication no. [NIH] 90-2789). Bethesda, MD, Department of Health and Human Services, 1990
26. Vogelstein B, Fearon ER, Hamilton SR, et al: Genetic alterations during colorectal-tumor development. N Engl J Med 319:525-532, 1988
27. Winawer SJ: Natural history of colorectal cancer. Am J Med 106:3S-6S, 1999
28. Greenberg ER, Baron JA, Tosteson TD, et al: A clinical trial of antioxidant vitamins to prevent colorectal adenoma: Polyp Prevention Study Group. N Engl J Med 331:141-147, 1994
29. Clark LC, Combs GF Jr, Turnbull BW, et al: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: A randomized controlled trial - Nutritional Prevention of Cancer Study Group. JAMA 276:1957-1963, 1996
30. Baron JA, Beach M, Mandel JS, et al: Calcium supplements for the prevention of colorectal adenomas: Calcium Polyp Prevention Study Group. N Engl J Med 340:101-107, 1999
31. Ho EE, Atwood JR, Benedict J, et al: A community-based feasibility study using wheat bran fiber supplementation to lower colon cancer risk. Prev Med 20:213-225, 1991
32. Alberts DS, Ritenbaugh C, Story JA, et al: Randomized, double-blinded, placebo-controlled study of effect of wheat bran fiber and calcium on fecal bile acids in patients with resected adenomatous colon polyps. J Natl Cancer Inst 88:81-92, 1996
33. Earnest DL, Sampliner RE, Roe DJ, et al: Progress report: The Arizona phase III study of the effect of wheat bran fiber on recurrence of adenomatous colon polyps. Am J Med 106:43S-45S, 1999
34. Hill MJ: Bile acids and colorectal cancer: Hypothesis, Eur J Cancer Prev 1:69-74, 1991 (suppl 2)
35. Fedorowski T, Salen G, Tint GS, et al: Transformation of chenodeoxycholic acid and ursodeoxycholic acid by human intestinal bacteria. Gastroenterology 77:1068-1073, 1979
36. Earnest DL, Holubec H, Wali RK, et al: Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res 54:5071-5074, 1994
37. Batta AK, Salen G, Holubec H, et al: Enrichment of the more hydrophilic bile acid ursodeoxycholic acid in the fecal water-soluble fraction after feeding to rats with colon polyps. Cancer Res 58:1684-1687, 1998
38. Alberts DS, Hixson L, Ahnen D, et al: Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase? J Cell Biochem Suppl 22:18-23, 1995
39. Thun MJ, Namboodiri MM, Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:1593-1596, 1991
40. Giardiello FM, Offerhaus JA, Tersmette AC, et al: Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: Evaluation of predictive factors. Gut 38:578-581, 1996
41. Rigau J, Pique JM, Rubio E, et al: Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 115:952-954, 1991
42. Winde G, Gumbinger HG, Osswald H, et al: The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: Clinical results of a dose-finding study on rectal sulindac administration. Int J Colorectal Dis 8:13-17, 1993
43. Smalley WE, Griffin MR: The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol Clin N Am 25:373-396, 1996
44. Kawamori T, Rao CV, Seibert K, et al: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58:409-412, 1998
45. Fort J: Celecoxib, a COX-2-specific inhibitor: The clinical data. Am J Orthopedics 28:13-18, 1999
46. Piazza GA, Rahm AL, Krutzsch M. et al: Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 55:3110-3116, 1995
47. Piazza GA, Alberts DS, Hixson LJ, et al: Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 57:2909-2915, 1997
48. Shen TY, Ham EA, Cirillo VJ, et al: Structure-activity relationship of certain prostaglandin synthetase inhibitors, in Robinson HJ, Vane JR (eds): Prostaglandin Synthetase Inhibitors. New York, NY, Raven Press, 1974, pp 18-31
49. Kelloff GJ, Crowell JA, Hawk ET, et al: Strategy and planning for chemopreventive drug development: Clinical development plans II. J Cell Biochem Suppl 26:54-71, 1996